Recce Pharmaceuticals: US Army to Evaluate R327 Gel for Burn Wounds | ASX:RCE, OTC:RECEF

Recce Pharmaceuticals Ltd is advancing research into a novel synthetic antibiotic, RECCE® 327 Gel (R327G), with a second Cooperative Research and Development Agreement (CRADA) now in place with the United States Army Institute of Surgical Research (USAISR). This collaboration focuses on evaluating R327G as a potential treatment for infected burn wounds, a significant medical challenge, particularly for military personnel.

The agreement, announced earlier this week, represents a substantial step forward for Recce Pharmaceuticals’ defense-focused research initiatives. It marks the company’s second CRADA with the US Army and its third research program overall with the US Department of Defense. According to James Graham, Managing Director and CEO of Recce Pharmaceuticals, infected burn wounds remain a critical concern for frontline warfighters.

Addressing the Threat of Antibiotic Resistance

The development of R327G is particularly noteworthy in the context of growing global antibiotic resistance. Traditional antibiotics, often derived from natural sources, face increasing challenges as bacteria evolve mechanisms to evade their effects. R327G, however, is a synthetically produced antibiotic designed to overcome these resistance mechanisms. As Dr. Graham explained, the synthetic nature of the antibiotic allows it to continue working effectively even with repeated use, a crucial advantage in treating persistent infections.

The World Health Organization (WHO) has identified antibiotic resistance as one of the greatest threats to human health. Notably, Recce Pharmaceuticals is currently the only company with a clinical-stage synthetic antibiotic, according to the WHO. This positions R327G as a potentially groundbreaking development in the fight against superbugs.

Burn Wound Research and the USAISR Collaboration

The current CRADA with the USAISR will involve evaluating R327G’s ability to reduce bacterial bioburden in infected burn wounds using a rat model developed by the USAISR – the Walker-Mason rat model. This model is a standard tool for assessing the efficacy of burn wound treatments. The research will specifically examine R327G’s effectiveness against Methicillin-Resistant Staphylococcus aureus (MRSA), a particularly dangerous antibiotic-resistant bacterium commonly found in burn wounds.

The collaboration with the US Army builds upon previous successful research led by Professor Fiona Wood, whose work paved the way for a smooth transition into the US program. This prior success demonstrates the potential of R327G and facilitated the partnership with the USAISR.

Beyond Burn Wounds: Diabetic Foot Infections and Potential Applications

While the current CRADA focuses on burn wounds, the potential applications of R327G extend beyond the battlefield. The same formulation of R327G is currently undergoing Phase III clinical trials for the treatment of diabetic foot infections, a common and serious complication of diabetes. This dual pathway – military and civilian – broadens the potential impact of the drug.

The potential for use within the Veterans Affairs (VA) healthcare system was also highlighted, suggesting a commitment to addressing the healthcare needs of veterans who may be particularly vulnerable to infections.

Financial Outlook and Future Prospects

Edison Research recently assigned a valuation of $3 per share to Recce Pharmaceuticals, reflecting the potential of its innovative antibiotic. Dr. Graham suggested that this valuation may be conservative, given the critical need for new antibiotics and the unique position of R327G as the only clinical-stage synthetic antibiotic recognized by the WHO. He emphasized that the company’s value is likely to increase as the threat of antibiotic resistance continues to grow.

The development of R327G represents a significant advancement in the search for new antibiotics capable of overcoming the challenges posed by antibiotic-resistant bacteria. The ongoing research, supported by collaborations with leading institutions like the USAISR, holds promise for improving the treatment of both military and civilian patients suffering from severe infections.